 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...678910111213141516...4748» |
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Rituxan (rituximab) / Roche
Trial initiation date, Combination therapy: A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL (clinicaltrials.gov) - Oct 30, 2023
P2, N=41, Recruiting, Sponsor: Zhejiang Cancer Hospital
Initiation date: Oct 2023 --> Jan 2023
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Ameile (aumolertinib) / Jiangsu Hansoh Pharma
New trial, Metastases: A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation (clinicaltrials.gov) - Oct 25, 2023
P=N/A, N=30, Recruiting, Sponsor: Kunming Medical University
- Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, J&J, Takeda
ADVERSE EVENT MANAGEMENT IN PATIENTS WITH PLATINUMRESISTANT OVARIAN CANCER TREATED WITH NIRAPARIB AND ANLOTINIB: UPDATES FROM THE PHASE II, MULTI-CENTER ANNIE STUDY () - Oct 25, 2023 - Abstract #IGCS2023IGCS_914;
The updated OS analysis showed sustained long-term efficacy of niraparib-anlotinib in PROC patients. The safety data reflected satisfactory tolerability and adverse event management, supporting the involvement of a multidisciplinary disease management team in ovarian cancer care.
- || Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial. (Pubmed Central) - Oct 22, 2023
P2
The combination of sintilimab and anlotinib demonstrated durable efficacy and was generally well tolerated in patients with NSCLC and uncommon EGFR mutations who had received prior standard-of-care treatments. (ClinicalTrials.gov identifier: NCT04790409).
- || Loqtorzi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study. (Pubmed Central) - Oct 22, 2023
Toripalimab combined with anlotinib was tolerable in EGFR-TKI-resistant advanced NSCLC patients not previously treated with chemotherapy. Patients without detectable EGFR mutation and high soluble PD-L1 levels may benefit from this chemotherapy-free treatment.
- | Retrospective data, Journal, Pleural effusion: Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: A Bayesian network meta-analysis. (Pubmed Central) - Oct 22, 2023
There are some concerns with the quality of the studies, and some limitations should be considered when interpreting these results, which includes limited geographical region and sample size of studies. Despite these limitations, this study may inform vascular targeting therapy choice in such a patient population.
- || Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Treatment of neurofibromatosis type II with anlotinib: a case report and literature review. (Pubmed Central) - Oct 22, 2023
Here, we present a case of NF2 that developed exacerbations after multiple treatments with gamma knife and surgery, and achieved good results after later treatment with anlotinib. Accordingly, we propose that anlotinib may be a valuable treatment option for NF2.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Rituxan (rituximab) / Roche
New P2 trial, Combination therapy: A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL (clinicaltrials.gov) - Oct 16, 2023
P2, N=41, Recruiting, Sponsor: Zhejiang Cancer Hospital
- || Halaven (eribulin mesylate) / Eisai
Clinical, Retrospective data, Journal, Metastases: Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study. (Pubmed Central) - Oct 16, 2023
Hematologic toxicity (leukopenia and neutropenia) was the most common grade ?3 AEs, and AEs were more common in patients in greater than or equal to third line. The results suggest that eribulin combined with antiangiogenic therapy has a meaningful clinical activity and an acceptable safety profile in HER2-negative MBC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Metastases: A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors. (Pubmed Central) - Oct 10, 2023
Most of the adverse reactions were grade 1-2, and there were no grade 4 adverse reactions. Anlotinib combined with anti-PD-1 inhibitors demonstrated promising efficacy and tolerable safety for patients with advanced solid tumors in the 2nd or later-line treatment.
- | 5-fluorouracil / Generic mfg.
Journal, IO biomarker: A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy. (Pubmed Central) - Oct 9, 2023
The patient received two cycles of modified FOLFIRINOX plus immune checkpoint inhibitor (Penpulimab)...Three cycles of combined therapy were adopted after surgery followed by maintained therapy with anlotinib plus Penpulimab. There was no evidence of tumor recurrence 19 months since diagnosis.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Interim analysis of the efficiency and Safety of Anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: A multicenter, single-arm, phase II study (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_1098;
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_1003;
P2
No treatment-related deaths occurred. Conclusions Given the encouraging anti-tumor activity and favorable tolerability, the combination of sintilimab and anlotinib could be an effective and safe option for NSCLC.
- Anniko (penpulimab) / Akesobio, Sino Biopharm
Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043) (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_998;
P2
There is no fatal AE related to Penpulimab or Anlotinib. Conclusions The results demonstrated that these new perioperative combinations of ICI and Anti-angiogenesis agent (Penpulimab and Anlotinib) with or without chemotherapy showed promising efficacy and with manageable safety profiles.
- Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_929;
3DP-OC demonstrated diverse drug responses, underlining its potential for precision medicine. Our ongoing research aims to correlate 3DP-OC drug responses with clinical outcomes.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_744;
P1/2
Conclusions Neoadjuvant therapy combining TQB2450 and anlotinib shows promising results, with a tolerable safety profile. The predictive role of the CRAFITY score for HCC prognosis is worth further exploration.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_718;
P2
Conclusions PAAG as first-line treatment demonstrated a promising efficacy and manageable AEs for mPC. Biomarkers identified in this study possessed the potential to guide the precise clinical application of PAAG.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_713;
P2
grade 3 TEAEs (43.9%) mainly included neutropenia (19.5%), white blood cell decreased (12.2%), and blood platelet decreased (9.8%). Conclusions Anlotinib plus chemotherapy as first-line treatment has shown promising efficacy and acceptable safety and maybe a favorable option for advanced LMs GI tumors, especially for pancreatic cancer.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_677;
P2
grade 3 TEAEs (33.3%) mainly included neutropenia (11.1%), hypertension (6.7%), and white blood cell decreased (6.7%). Conclusions Anlotinib plus chemotherapy as first-line treatment has shown promising efficacy and acceptable safety and maybe a favorable option for advanced LMs CRC tumors.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Chemotherapy regimen for recurrent uterine leiomyosarcoma. (Pubmed Central) - Oct 3, 2023
Conclusions Anlotinib plus chemotherapy as first-line treatment has shown promising efficacy and acceptable safety and maybe a favorable option for advanced LMs CRC tumors. It is important to comprehensively consider the patient's condition, and fully consider the efficacy, dosage, and adverse reactions of the chemotherapy regimen to determine the appropriate plan, in order to achieve the best therapeutic benefits for patients.
- | AiTan (rivoceranib) / HLB Bio Group
Biomarker, Trial completion date, Trial primary completion date, Metastases: BIOVAS: BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (clinicaltrials.gov) - Oct 3, 2023
P2, N=30, Recruiting, Sponsor: Ruijin Hospital
It is important to comprehensively consider the patient's condition, and fully consider the efficacy, dosage, and adverse reactions of the chemotherapy regimen to determine the appropriate plan, in order to achieve the best therapeutic benefits for patients. Trial completion date: Aug 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
- | AL8326 / Advenchen
Trial completion date, Trial primary completion date: Phase 2 Safety and Efficacy Evaluation of AL8326 in ?2nd Line SCLC (clinicaltrials.gov) - Oct 3, 2023
P2, N=36, Recruiting, Sponsor: Advenchen Pharmaceuticals, LLC.
Trial completion date: Aug 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> Feb 2024 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker: Exploring the Efficacy and Molecular Mechanism of Systemic Therapy-Based Split-Course Stereotactic Body Radiation Therapy for Solid Tumors. (Pubmed Central) - Oct 3, 2023
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 In preclinical models, the combination of split SBRT with systemic therapy has been shown to be more advantageous than conventional segmentation, possibly by affecting immune cell infiltration in the tumor microenvironment and reducing tumor hypoxia.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial: Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Oct 2, 2023
P=N/A, N=10, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia. (Pubmed Central) - Oct 1, 2023
In preclinical models, the combination of split SBRT with systemic therapy has been shown to be more advantageous than conventional segmentation, possibly by affecting immune cell infiltration in the tumor microenvironment and reducing tumor hypoxia. No abstract available
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment. (Pubmed Central) - Sep 29, 2023
In the anlotinib group, treatment-related adverse events were reported in 15 patients (44.1%), with acute or late grade 3-5 adverse events identified in 14.7% of patients (n = 5). WBRT plus anlotinib, as a convenient chemo-free regimen, may represent an overall safe and effective procedure in advanced NSCLC with multiple BMs that progressed or developed after standard systematic treatment.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, Metastases: Anlotinib as a maintenance treatment for advanced soft tissue (Pubmed Central) - Sep 28, 2023
P2
Postchemotherapy maintenance treatment with anlotinib exhibits promising efficacy and tolerable toxicity in patients with advanced STS. Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the National Key Research and Development Program of China, and the National Natural Science Foundation of China.
- | Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (clinicaltrials.gov) - Sep 26, 2023
P2, N=30, Recruiting, Sponsor: Shanghai Changzheng Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the National Key Research and Development Program of China, and the National Natural Science Foundation of China. Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Dec 2023
- | Loqtorzi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Efficacy of first-line immunization combined with antiangiogenesis treatment and chemotherapy for the treatment of tongue cancer: A case report. (Pubmed Central) - Sep 25, 2023
Here, we describe 2 cases of locally advanced oral cancer treated with first-line immune checkpoint inhibitors in combination with targeted therapy and chemotherapy. This approach was successful in these patients, but a larger sample size is required to verify our findings.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer (clinicaltrials.gov) - Sep 25, 2023
P2, N=134, Recruiting, Sponsor: Henan Cancer Hospital
This approach was successful in these patients, but a larger sample size is required to verify our findings. Trial primary completion date: May 2023 --> Sep 2024
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: RCT-PAAG: Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 25, 2023
P2, N=177, Recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study. (Pubmed Central) - Sep 23, 2023
Trial primary completion date: May 2023 --> Sep 2024 In this study, pyrotinib plus antiangiogenic agents demonstrated promising efficacy and were tolerable in HER2-altered NSCLC patients.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Ameile (aumolertinib) / Jiangsu Hansoh Pharma
New P3 trial, Metastases: Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance (clinicaltrials.gov) - Sep 21, 2023
P3, N=98, Recruiting, Sponsor: Qianfoshan Hospital
- | paclitaxel / Generic mfg.
New P3 trial, Metastases: A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody (clinicaltrials.gov) - Sep 21, 2023
P3, N=52, Not yet recruiting, Sponsor: Degan Lu
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Enrollment change, Combination therapy: Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 21, 2023
P1/2, N=33, Completed, Sponsor: Zhejiang Cancer Hospital
In this study, pyrotinib plus antiangiogenic agents demonstrated promising efficacy and were tolerable in HER2-altered NSCLC patients. Unknown status --> Completed | N=20 --> 33
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal: Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001). (Pubmed Central) - Sep 20, 2023
Anlotinib plus XELOX as first-line therapy in patients with mCRC showed anti-tumor activity and safety profile, which is worth further investigation. chictr.org.cn, identifier ChiCTR1900028417.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Journal, PD(L)-1 Biomarker, IO biomarker: A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer. (Pubmed Central) - Sep 19, 2023
Anlotinib plus TQB2450 demonstrated promising antitumor activities in advanced NSCLC patients without EGFR and ALK alterations and the toxicities were overall manageable. The study findings support the continued development of TQB2450 plus anlotinib for advanced NSCLC patients without driver gene alterations.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Real-world evidence, Real-world, Metastases: Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study. (Pubmed Central) - Sep 18, 2023
Immunotherapy combination with anlotinib significantly improved PFS. The efficacy of anlotinib may be impaired by previous antiangiogenic therapy, which can be investigated in further studies.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Tumor mutational burden, IO biomarker, Metastases: Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations (clinicaltrials.gov) - Sep 14, 2023
P2, N=21, Completed, Sponsor: Zhejiang Cancer Hospital
The efficacy of anlotinib may be impaired by previous antiangiogenic therapy, which can be investigated in further studies. Active, not recruiting --> Completed
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date: Anlotinib Capsules in the Treatment for IPF/PF-ILDs (clinicaltrials.gov) - Sep 13, 2023
P2/3, N=30, Recruiting, Sponsor: First Affiliated Hospital of Wenzhou Medical University
Active, not recruiting --> Completed Trial primary completion date: Jul 2023 --> Jul 2024
- | Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date: NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov) - Sep 13, 2023
P2, N=31, Recruiting, Sponsor: Guangdong Provincial People's Hospital
Trial primary completion date: Jul 2023 --> Jul 2024 Trial primary completion date: Dec 2023 --> Aug 2023
- | Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1/2 trial, Metastases: Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC (clinicaltrials.gov) - Sep 13, 2023
P1/2, N=25, Not yet recruiting, Sponsor: Sichuan University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Enrollment open, Metastases: Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer (clinicaltrials.gov) - Sep 13, 2023
P2, N=20, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
Trial primary completion date: Dec 2023 --> Aug 2023 Not yet recruiting --> Recruiting
- | Journal: A case series on the efficacy and safety of a PD-1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI-H endometrial cancer. (Pubmed Central) - Sep 13, 2023
The overall objective response rate was 100%. PD-1 inhibitors combined with antiangiogenic agents may have good therapeutic effects on patients with recurrent MSI-H endometrial cancer and may become an important method for the treatment of recurrent endometrial cancer in the future.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal: Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: a single-arm, prospective, phase II study. (Pubmed Central) - Sep 11, 2023
Patients were generally able to tolerate treatment with anlotinib and exhibited a favorable prognosis. Anlotinib achieved prospective efficacy and manageable safety in the maintenance treatment of ES-SCLC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence. (Pubmed Central) - Sep 11, 2023
In the anlotinib group, 19 of 27 patients (70.4%) experienced treatment-emergent adverse events, with the most common events (?10%) being hypertension (22.2%) and decreased platelet count (22.2%). The results indicate that anlotinib, as a new, orally administered tyrosine kinase inhibitor, has the same efficacy as TACE, and side effects can be well controlled.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China. (Pubmed Central) - Sep 11, 2023
The cost-effectiveness acceptability curves showed that the base-case analysis results were relatively stable. Considering the clinical efficacy, safety, and cost-effectiveness of anlotinib, it may be a valuable third-line or further treatment for advanced NSCLC in China.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P2 trial, Checkpoint inhibition, Metastases: FAITH: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (clinicaltrials.gov) - Sep 11, 2023
P2, N=55, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib Attenuates Liver Fibrosis by Regulating the Transforming Growth Factor ?1/Smad3 Signaling Pathway. (Pubmed Central) - Sep 8, 2023
In animal experiments, anlotinib showed protective effects on the CCl4-induced liver damage, including ameliorating liver inflammation, reversing liver fibrosis and reducing liver enzymes. This is a very good signal, anlotinib may be useful for halting or reversing the progression of liver fibrosis and could be employed in the development of novel therapeutic drugs for the management of chronic liver diseases.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Real-world evidence, Real-world, Metastases: Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study. (Pubmed Central) - Sep 7, 2023
This is a very good signal, anlotinib may be useful for halting or reversing the progression of liver fibrosis and could be employed in the development of novel therapeutic drugs for the management of chronic liver diseases. The median progression-free survival of patients in the monotherapy group was significantly lower than that in the combination group (5 vs 6